Fusion Antibodies

14 results

Established in 2001, Fusion provides a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion Antibodies gets green light from investors for £3m rights issue

Fusion Antibodies, a Belfast-based contract research firm, has secured shareholder approval for a €3 million rights issue. The London-listed company,(...)

Fusion Antibodies will use the funds to expand its antibody library.
Fusion Antibodies announces £3m share placing to help fund Covid-19 work

Northern Ireland contract research company Fusion Antibodies has announced a £3 million share placing to expand its mammalian antibody library to incl(...)

Covid-19 pandemic has ‘limited impact’ on Fusion Antibodies

Northern Ireland contract research company Fusion Antibodies has so far had a “very limited impact” from the Covid-19 pandemic, with the company remai(...)

The company, listed on London’s AIM exchange, said trading in its financial third quarter continued the favourable trends seen in the first half of the year. Photograph: iStock
Revenues to be ‘materially ahead’ of previous year at Fusion Antibodies

Northern Ireland contract research company Fusion Antibodies posted a positive trading update on Wednesday, forecasting full year revenues to come in (...)

Fusion Antibodies is confident of significant revenue growth in the second half of the year
Fusion Antibodies sees revenue continue to grow

Fusion Antibodies, a pharmaceutical contract research company with its headquarters in Belfast, said revenue continued to grow in the six months to th(...)

Belfast research contract group Fusion Antibodies reported record second-half revenues as it moves past AIM-listing pressures.
Fusion Antibodies sees full year revenues dip 19%

Northern Ireland contract research company Fusion Antibodies recorded a 19 per cent fall in full year revenues to £2.2 million on the back of a weak f(...)

Photograph: iStock
Fusion Antibodies confirms second-half pick-up in revenue

Belfast-based Fusion Antibodies said its performance in the second half of the year ended March 31st improved as orders and revenues significantly inc(...)

Paul Kerr, chief executive of Fusion Antibodies.
Fusion Antibodies warns of weaker revenues for 2019

Northern Ireland contract research company Fusion Antibodies warned that revenues for the year ended March 31st would be “materially below current mar(...)

Fusion Antibodies CEO Paul Kerr said it had been a challenging period but company had ‘turned a corner’.
Losses at Fusion Antibodies quadruple in ‘challenging’ period

Losses at Belfast pharmaceutical company Fusion Antibodies quadrupled in the six months ended September 30th compared with the same period last year, (...)

Fusion Antibodies has a particular focus on the production of antibodies in a lab. Photograph: iStock
Fusion Antibodies reports £700,000 loss for first trading year

Fusion Antibodies, the Northern Ireland contract research company, has reported losses of nearly £700,000 (€781,000) for its maiden year as an AIM-lis(...)

  • 1
  • 2
  • Next ›
  • Last »